 |
Filgrastim |
|---|---|
| Trade Name | Neupogen |
| Orphan Indication | For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy |
| USA Market Approval | USA |
| USA Designation Date | 1995-07-17 00:00:00 |
| Sponsor | Amgen, Inc.;1840 Dehavilland Drive;Thousand Oaks, California, 91320 |
